Crinetics Pharmaceuticals filed an 8-K to supplement its proxy statement regarding the proposed $10 billion acquisition by Vertex Pharmaceuticals. The filing discloses updated financial projections from J.P. Morgan and Leerink Partners, valuing Crinetics at $68.25–$86.00 per share via DCF analysis and confirming a merger consideration of $85.00 per share. It also reveals that the board discussed a pending derivative lawsuit alleging excessive director compensation but deemed it immaterial relative to the transaction value, and noted voluntary discussions with Vertex about potential post-merger retention of Crinetics management without committed terms. The special shareholder meeting to approve the merger is scheduled for August 28, 2026. Crinetics Pharmaceuticals operates in the biotechnology industry, developing therapies for rare diseases.
